以Trop-2为靶点的抗体偶联药物国内外研究进展

Development of ADC drugs targeting Trop-2 at home and abroad

人滋养细胞表面抗原2(Trop-2)是一种细胞表面的跨膜糖蛋白,在多种肿瘤(如乳腺癌、非小细胞肺癌、胰腺癌、胃癌、结肠癌等)中高表达,且其高表达与预后不良相关。T r o p-2作为肿瘤治疗的热门靶点,国内外已研发出多款Trop-2靶向的抗体偶联药物(ADC),其中一款已成功上市。本文就Trop-2为靶向的ADC在国内外的研究进展进行综述。

Trophoblast cell surface antigen 2(Trop-2)is a kind of transmembrane glycoprotein on the cell surface,which is highly expressed in various tumors(breast cancer,non-small cell lung cancer,pancreatic cancer,gastric cancer,colon cancer,e.g.).Its high expression is associated with poor prognosis.As a popular target for tumor therapy,many Trop-2-targeted ADC drugs have been developed at home and abroad,one of which has successfully marketed.This paper reviews the research progress of the drugs at home and abroad.